HEBP1

Across TCGA pan-cancer cohorts, HEBP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HEBP1 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher HEBP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEBP1 expression acts as an unfavorable survival marker.

MESO, LIHC, and SARC are the cancer types where HEBP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	II,III,IV	0.127	0.411	.013	12	view →
LIHC	DFS	Median	All	0.090	0.555	.001	12	view →
SARC	OS	Median	All	0.174	0.745	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HEBP1–MESO (DFS)

Open the MESO breakdown →